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Background.Subtotalthyroidectomyisasurgicalprocedure,inwhichthesurgeonleavesasmallthyroidremnantinsitutopreserve
thyroid function, thereby preventing lifelong thyroid hormone supplementation therapy. Aim. To evaluate thyroid function after
subtotal thyroidectomy for Graves’ hyperthyroidism. Subjects and Methods. We retrospectively reviewed the medical records of all
patients (n = 62) who underwent subtotal thyroidectomy for recurrent Graves’ hyperthyroidism between 1992 and 2008 in our
hospital. Thyroid function was deﬁned according to plasma TSH and free T4 values. Results. Median followup after operation
was 54.6 months (range 2.1–204.2 months). Only 6% of patients were euthyroid after surgery. The majority of patients (84%)
became hypothyroid, whereas 10% of patients had persistent or recurrent hyperthyroidism. Permanent recurrent laryngeal nerve
palsy and permanent hypocalcaemia were noted in 1.6% and 3.2% of patients, respectively. Conclusion. In our series, subtotal
thyroidectomy for Graves’ hyperthyroidism was associated with a high risk of postoperative hypothyroidism and a smaller, but
signiﬁcant, risk of persistent hyperthyroidism. Our data suggest that subtotal thyroidectomy seems to provide very little advantage
over total thyroidectomy in terms of postoperative thyroid function.
1.Introduction
Graves’ disease is the most common cause of hyperthy-
roidism [1]. Three treatment modalities are available for
the treatment of hyperthyroidism: antithyroid medication,
radioiodine therapy, and surgery. According to the recent
guidelines on the treatment of hyperthyroidism from The
American Thyroid Association and The American Associa-
tion of Clinical Endocrinologists [2], patients with Graves’
hyperthyroidism can be treated with any of these treatment
options. Factors favoring a particular treatment and con-
traindications for certain treatment options are discussed in
the guidelines. Physicians should inform patients on poten-
tial side eﬀects and beneﬁts of each option before making a
decision. There is a wide geographic variation in the choice
of therapy [3–6]. Medical treatment with antithyroid drugs
is often accepted as ﬁrst-choice modality in Europe, followed
by radioiodine in case of recurrence. Although surgery
oﬀers the advantage of quick control and low morbidity in
experienced hands, it is infrequently recommended as initial
treatment. Surgery is indicated for recurrent Graves’ disease,
when other therapeutic options are contraindicated and in
patients with large goiters.
Two diﬀerent surgical techniques are used for the
treatment of Graves’ hyperthyroidism: a total thyroidectomy
(TT) and a subtotal thyroidectomy (STT), which leaves a
small unilateral or bilateral remnant in situ. While there is
general consensus that total thyroidectomy is the procedure
of choice in patients with thyroid carcinoma, the optimal
surgical approach for benign thyroid disease has remained
controversial. The main reason for performing a subtotal
thyroidectomy is a presumably lower incidence of postop-
erative complications, including recurrent laryngeal nerve
(RLN)paralysisandhypoparathyroidism,andananticipated
postoperative euthyroid state by leaving a small remnant of
thyroid tissue in situ to maintain adequate hormone produc-
tion. There is, however, a risk that the disease will persist or
recur in the remnant. More recent studies favoured TT as2 The Scientiﬁc World Journal
preferred procedure in the surgical management of Graves’
disease, because the residual function after STT was not as
good as previously believed and the complication rates were
not diﬀerent between the TT and STT procedure [7–10].
The aim of this retrospective study was to evaluate
the long-term treatment outcome of patients treated with
subtotal thyroidectomy for Graves’ disease in our institution.
We recorded postoperative thyroid function, along with the
postoperative complication rates, to determine if subtotal
thyroidectomy should still play a role in the surgical man-
agement of Graves’ hyperthyroidism.
2. Methods
2.1. Patients. All operation records of patients surgically
treatedforthyroiddiseasebetweenJanuary1992andDecem-
ber 2008 were reviewed to identify patients treated with
subtotal thyroidectomy for Graves’ disease. Patients were
diagnosedwithGraves’diseasebasedonpatienthistory,clin-
ical examination, hormonal and/or immunologic assays, and
thyroid scintigraphy. Charts, medical records, and corre-
spondence of all departments involved in the treatment were
retrospectively reviewed for data collection.
2.2. Procedure and Followup. Patients were pretreated with
antithyroid medication and/or with amiodarone, ipodate,
or Lugol’s solution to achieve euthyroidism on the day of
surgery.
Mostoperationsbefore2000wereperformedbythesame
surgeon; thereafter, two additional surgeons also operated
these patients. All three surgeons had extensive experience in
thyroid surgery. For each subtotal thyroidectomy, a standard
surgical technique was used. All patients underwent a unilat-
eral subtotal hemithyroidectomy, leaving approximately 5–
8grams of thyroid tissue, and a contralateral total hemithy-
roidectomy.
Pre- and postoperatively, patients underwent direct
laryngoscopy to check for vocal cord paralysis. Recurrent
laryngeal nerve palsy was deﬁned as permanent if it persisted
more than 12 months postoperatively. Serum calcium levels
were routinely measured four hours after surgery and at
least once daily during hospital stay. Hypocalcaemia was
deﬁned as a serum calcium level <2.20mmol/L (reference
range 2.20–2.60mmol/L). Oral or intravenous calcium
and/or calcitriol suppletion was given when serum calcium
level was <1.80mmol/L and/or when symptoms developed.
Permanent hypoparathyroidism was deﬁned as requirement
of calcitriol supplementation to maintain normal serum
calcium levels 12 months after surgery.
Postoperatively, patients were assessed clinically and
biochemically. Thyroid status was determined by measuring
plasma thyroid-stimulating hormone (TSH): reference val-
ues 0.40–4.00mU/L until 2007 and 0.50–5.00mU/L as of
2008, free thyroxine (FT4): reference values 10–20pmol/L
until 1995 and 10–23pmol/L as of 1996, and triiodothyro-
nine (T3): reference values 1.30–2.70nmol/L. Patients were
classiﬁed as postoperative hypothyroid, in the case of FT4
levels below the reference range and/or elevated TSH levels
Table 1: Patient characteristics.
Characteristic N (%) or
median (range)
Age at diagnosis (years) 32 (11–63)
Age at surgery (years) 34.5 (19–63)
Time between diagnosis and surgery (months) 26.5 (3–112)
Sex
Female 56 (90.3%)
Male 6 (9.7%)
Surgical indication
Failed medical treatment 54 (87.1%)
Mechanical obstruction 2 (3.2%)
Cosmetic 2 (3.2%)
Patient preference/refusal radioactive iodine
treatment 2 (3.2%)
Cold nodule 1 (1.6%)
Pregnancy wish 1 (1.6%)
Preoperative radioactive iodide treatment
No 49 (79.0%)
Yes 13 (21.0%)
Previous medical treatment
Antithyroid drugs (+ thyroxine + β-blocker) 62 (100%)
Duration of thyrostatic treatment (months) 23 (4–73)
Medical treatment at the time of surgery
Antithyroid drugs 45 (72.6%)
Antithyroid drugs + amiodarone, Lugols or
ipodate 11 (17.7%)
Amiodarone 1 (1.6%)
Ipodate 5 (8.1%)
on at least two consecutive measurements. These patients
were prescribed thyroid hormone replacement therapy.
Postoperatively persistent or recurrent elevated FT4 and/or
T3 with suppressed TSH levels indicated hyperthyroidism.
Euthyroidismwasdeﬁned asa serumTSH within the normal
range.
All patients were sent a questionnaire to ask them about
their current need for thyroid hormone supplementation
and the date on which it had been started. If patients did
not return the questionnaire, general physicians or local
endocrinologists were contacted to learn more about the
patient’s current thyroid status and thyroid hormone use.
Eachpatienthadavariablefollowupschedule,depending
on the postoperative endocrine status, physician’s opinion,
and patient preference. The followup was deﬁned as the
interval between thyroid surgery and the date on which the
last known information on the thyroid functional status was
retrieved.
2.3. Statistical Analysis. The statistical package SPSS (version
16.0.2;SPSS,Inc.,Chicago,IL)wasused.Resultsarereported
as median and range for interval variables. For nominal
variables, numbers and percentages are given.The Scientiﬁc World Journal 3
Table 2: Thyroid function after subtotal thyroidectomy for Graves’ disease.
Study Type of surgery No. of patients Followup Postoperative thyroid function (%)
Hypothyroid Euthyroid Hyperthyroid
Andaker et al. [12] (1992) BST 23 3.6 (3-4) years 34.8 60.9 4.3
STT 27 3.6 (3-4) years 44.4 55.6 0
Chi et al. [5] (2005) BST 166 26.4 ±1.1 months 21.1 69.9 9.0
STT 174 26.4 ±1.1 months 26.4 71.8 1.7
Chou et al. [19] (1999) BST 205 26.9 ±15 (9–97) months 44.2 48.7 7.0
Ku et al. [7] (2005) BST 119 65 (6–104) months 72.3 21.8 5.9
Kuma et al. [15] (1991) STT 67 8.8 ±1.5 years 32.9 56.7 10.4
Lal et al. [3] (2005) STT 30 6–120 months 83.3 10.0 6.7
Le Clech et al. [14] (2005) STT 312 ? 23.7 70.3 6.0
Lepner et al. [11] (2008) STT 21 49 (24–70) months 66.7 33.3 0
Miccoli et al. [17] (1996) STT 80 6–48 months 46.3 46.3 7.5
Moreno et al. [16] (2006) BST 202 5 years 62.1 35.5 2.4
Robert et al. [20] (2001) STT 56 7 (1–15) years 73 23 4
Sivanandan et al. [13] (2004) BST 213 5 years 28.2 56.8 15.0
Sugino et al. [21] (1995) STT 728 42.5 (24–58) months 46.4 39.0 14.6
Present study (2010) STT 62 55 (2–204) months 83.9 6.5 9.7
3. Results
3.1. Patient Characteristics (Table 1). A total of 64 patients
with a subtotal thyroidectomy for Graves’ hyperthyroidism
were identiﬁed. Two patients were excluded because of
histologically demonstrated malignancy of the thyroid gland
requiring additional treatment. Therefore, 62 patients were
analyzed.
Of the patients studied, 56 were women (90.3%) and 6
were men (9.7%), who were 34.5 (19–63) years of age at the
time of surgical intervention. The interval from diagnosis
to surgical intervention was 26.5 (3–112) months. The most
frequentindicationforsurgerywasfailureofmedicaltherapy
(n = 54, 87.1%). Patients were considered to have failed
medical therapy if they were incompliant (n = 6, 9.7%),
had an allergic reaction to medication (n = 7, 11.3%), or
had no resolution or even recurrence of symptoms, after
a course of therapy with either antithyroid medication,
radioiodine or both (n = 41, 66.1%). All patients taking
part in this study received previous medical treatment con-
sisting of antithyroid drugs (ATD), alone or combined with
levothyroxine. The antithyroid drugs were administrated for
4 to 73 months, with a median of 23 months. β-adrenergic
blocking drugs were given in all patients for symptomatic
relieve. Radioiodine therapy had been given to 13 (21.0%)
of the 62 patients in the years before the operation. 17
patients (27.4%), who did not achieve euthyroidism as
an outpatient with regular antithyroid medication due to
noncompliance, resistance, or intolerance, were admitted
and clinically treated with amiodarone, ipodate, or Lugol’s
solution preceding surgery.
3.2. Long-Term Postsurgical Followup. Patients had a post-
operative followup of 54.6 (2.1–204.2) months. Hypothy-
roidism occurred in 52 (83.9%) patients, 1.3 (0.2–34.2)
months after surgery. In three patients postoperative
hypothyroidism was diagnosed based on a high TSH with
a normal free T4. From these 52 patients, the thyroid
hormone status was based on recent data in 42 patients.
We were unable to trace the remaining 10 patients, who
were no longer with their last known general practitioner
and whose current address was unavailable. These patients
were discharged from further followup at the outpatient
clinic 16.3 (0.7–69.7) months after surgery and 15.7 (2.1–
70.9) months after being diagnosed with postoperative
hypothyroidism. Four patients remained euthyroid during
post-operative followup. Information on the thyroid status
from the 4 euthyroid patients was retrieved 62.6 months
after surgery (range 6.1–96.4 months). Six patients exhibited
recurrent or persistent hyperthyroidism during the post-
operative followup. The median time between the surgical
treatment and the presence of hyperthyroidism was 9.7
months (range 1.1–86.3 months).
3.3. Surgical Complications. Permanent hypoparathyroidism
was present in 2 (3.2%) patients. Only 1 (1.6%) patient
developedpermanentrecurrentlaryngealnerveinjury.There
was no surgical mortality.
4. Discussion
This study demonstrates that the majority of patients
with Graves’ disease (83.9%) developed thyroid hormone
deﬁciency after subtotal thyroidectomy. In addition, hyper-
thyroidism persisted or recurred in almost 10% of patients,
whereas euthyroidism was established in only 6.5% of
patients.
We compared our results to previously published studies
evaluating thyroid status after subtotal thyroidectomy for
Graves’ disease (Table 2). The reported postoperative thyroid
function outcomes vary, with hypothyroid rates ranging4 The Scientiﬁc World Journal
from 21.1% [6] to 83.3% [3]. The incidence of hypothy-
roidism in the present study seems to be relatively high
compared to these studies, although two studies carried
out in 2005 presented hypothyroid rates of 72.3% [7]
and 83.3% [3]. Our recurrence rate of almost 10% is
comparable to previously published data, with recurrence
rates ranging from 0% [11, 12] to 15% [13]. The presence
of recurrence in the thyroid remnant makes subsequent
medical, surgical, or radioactive treatment necessary, with
potential additional risks. This is reﬂected in the recently
publishedguidelinefromTheAmericanThyroidAssociation
and The American Association of Clinical Endocrinologists
on treatment of hyperthyroidism [2]. If surgery is chosen
as primary treatment for Graves’ hyperthyroidism, the
guidelines recommend near-total or total thyroidectomy
as procedure of choice, due to the high persistence and
recurrence rates following subtotal thyroidectomy.
The highest percentage of patients with euthyroidism is
reported by Chi et al. [5]a n dL eC l e c he ta l .[ 14], 71.8%
and 70.3%, respectively. One possible explanation for the
variation in postoperative thyroid status rates is a varying
amount of thyroid tissue left behind. The reported estimated
weight of the thyroid remnant ranged from 1gram on one
side [3] to 6-7grams in total [15]. Twenty-one percent of
our patients underwent radioactive iodine therapy in the
years preceding the surgery. This may have contributed
to the relatively high postoperative hypothyroidism rate
in our study. Unfortunately, information on radioactive
iodine treatment was not reported in other studies. Another
possible explanation for the variation in reported rates of
postoperative hypothyroidism may be variation in the study
populations, for example, in terms of sex, age, and disease
severity. The fact that our hospital serves as an academic
referral center presumably introduces bias towards a more
severely ill and therapy-resistant patient group. Therefore,
the main indication for surgery in our study was failure of
medical treatment. This was also reported by another study
with a relatively high rate of postoperative hypothyroidism
[16]. Finally, the duration of postoperative followup varied
considerably between studies, ranging from several months
in some studies to several years in others. Most patients who
became hypothyroid in our study tended to do so early.
Because only a limited number of patients received pre-
operative preparation with iodine-containing medication,
this probably does not explain the high hypothyroid rates
found in this study.
The main reasons to perform a subtotal thyroidec-
tomy are to prevent postoperative hypothyroidism and
complications associated with the total procedure. Given
that euthyroidism was achieved in only a minority of
cases, the only remaining argument in favor of STT is the
assumed lower complication rate. In our series, permanent
hypoparathyroidism was present in 3.2% of our patients.
Permanent hypoparathyroidism has been reported to range
from 0.6% [5]t o3 . 8 %[ 17] in subtotal thyroidectomies.
Recurrent laryngeal nerve paralysis occurred in 1.6% of our
patients, comparable with reported rates ranging from 0%
[5]t o1 . 9 %[ 18]. In this study we did not compare STT
andTTintermsofpermanentcomplicationrates.Previously
published studies have shown that the risk of permanent
complications with TT is no greater than that with STT [7–
10].
In conclusion, in our series on subtotal thyroidectomy
for Graves’ hyperthyroidism euthyroidism was achieved in
only a small proportion of patients. The majority of patients
becamehypothyroidaftersurgery,andapproximately10per-
cent had recurrent or persistent hyperthyroidism requiring
additional treatment. These ﬁndings highlight the impor-
tance of continuing systematic evaluation of treatment
results to optimize patient counseling. Our data favor total
over subtotal thyroidectomy as the preferred surgical treat-
ment for Graves’ hyperthyroidism.
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